Alcon has announced the CE Mark approval of its Clareon Vivity intraocular lenses (IOLs) in Europe, signalling the start of its commercial release in early Q2 2025.
The Swiss-American eye care company is making the Clareon Vivity available on its advanced lens material, Clareon, thus expanding visual correction options across Europe.
Clareon Vivity utilises an extended depth of focus (EDOF) approach and is designed for patients, including those with mild comorbidities such as age-related macular degeneration, glaucoma, and post-refractive conditions.
It promises improved vision from distance to near with minimal visual disturbances. Studies reveal that over 90% of patients have expressed satisfaction with the outcomes, noting an enhanced range of vision.
This lens model incorporates UV-absorbing and blue-light-filtering properties and employs X-WAVE Technology for a continuously extended focal range. The design aims to reduce dependency on spectacles while offering stable distance, intermediate, and near vision without compromising contrast sensitivity under low light conditions.
Its STABLEFORCE Haptics are engineered for reliable axial and rotational stability.
Alcon surgical franchise, Europe vice president Sunil Vasanth said: “When we created Vivity, our goal was to develop an innovative lens that would minimise patients’ reliance on glasses and simplify presbyopia correction for surgeons. We achieved this by designing a real EDOF lens, which has quickly become the world’s most implanted EDOF.
“This lens is now available in our most advanced biomaterial to date, Clareon.”
Despite the promising benefits, potential risks accompany the procedure. Complications could range from temporary side effects like irritation and swelling to more severe issues requiring further treatment.
Patients with pre-existing conditions such as diabetes might face elevated risks.
With the addition of Clareon Vivity, European surgeons now have broader access to Alcon’s suite of IOLs, including Clareon Monofocal and Clareon PanOptix models. These lenses are available in various configurations, including toric variants for astigmatism correction, and can be inserted using either the manual Clareon Monarch IV or the automated AutonoMe delivery systems.
Earlier this week, Alcon disclosed its acquisition of LENSAR in a transaction valued at approximately $430m. This acquisition encompasses the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology, and the LENSAR legacy laser system, thereby enhancing Alcon’s femtosecond laser-assisted cataract surgery (FLACS) capabilities.
